View More Recent Stories

Apr 11, 2022 02:30PM Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting
Mar 22, 2022 08:00AM Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
Mar 15, 2022 07:00AM Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting
Feb 11, 2022 08:17AM Kintara Therapeutics (KTRA) Reports Q2 EPS of ($0.12), $14M Cash on Hand, Issues Business Update
Feb 11, 2022 08:15AM Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update
Feb 4, 2022 07:00AM Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022
Feb 3, 2022 07:00AM Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells
Jan 12, 2022 08:00AM Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma
Jan 5, 2022 08:00AM Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference
Dec 7, 2021 08:00AM Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021
Nov 30, 2021 08:00AM Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma
Nov 18, 2021 08:03AM Kintara Therapeutics (KTRA) Presents VAL-083 Phase 2 Updates
Nov 18, 2021 08:00AM Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society for Neuro-oncology Annual Meeting
Nov 15, 2021 08:15AM Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate Update
Nov 11, 2021 08:30AM Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021
Nov 9, 2021 08:00AM Kintara Announces Changes to Executive Leadership Team
Oct 11, 2021 08:00AM Kintara Therapeutics to Present at the LD Micro Main Event Conference
Sep 28, 2021 01:33PM Kintara Announces Closing of $15.0 million Offering Priced at a Premium to Market
Sep 24, 2021 08:01AM Kintara Therapeutics (KTRA) Announces 12M Share and Warrant Offering at $1.25/sh
Sep 24, 2021 08:00AM Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market
Sep 22, 2021 08:02AM Kintara Therapeutics (KTRA) Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Sep 22, 2021 08:00AM Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Aug 12, 2021 08:00AM Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021
Aug 4, 2021 08:00AM Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021
Jul 1, 2021 08:19AM Kintara Therapeutics (KTRA) Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Jul 1, 2021 08:00AM Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Jun 3, 2021 08:08AM Kintara Therapeutics (KTRA) Enrolls Final Patient in Phase 2 Trial of VAL-083 for Brain Tumors
Jun 3, 2021 08:00AM Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
Jun 2, 2021 08:00AM Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
May 5, 2021 08:00AM Kintara Therapeutics to Participate at the Benzinga Global Small Cap Conference
Apr 12, 2021 08:00AM Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting
Mar 17, 2021 08:00AM Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference
Mar 10, 2021 08:00AM Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth Virtual Conference
Mar 3, 2021 08:00AM Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer
Mar 2, 2021 08:00AM Kintara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 17, 2021 08:08AM Kintara Therapeutics (KTRA) Reports Final Patient Enrollment in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Feb 17, 2021 08:00AM Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
Jan 13, 2021 08:00AM Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
View More Recent Stories